Clinical trials

At Octapharma, we are committed to better understanding von Willebrand disease and to improving the care of people with this condition.


Over 15 years of clinical and real-life experience have already proven the efficacy and tolerability of wilate® in people with all types of von Willebrand disease for surgery, prophylaxis and on-demand treatment.1-3 However, there is still more to learn. We continue to work with the scientific and clinical community to improve our understanding of von Willebrand disease, and are proud to support numerous clinical trials and investigator-initiated studies.

Published clinical trials with wilate®

in people with von Willebrand disease

Ongoing studies in von Willebrand disease

As part of Octapharma’s long-standing commitment to addressing the unmet clinical needs of people with von Willebrand disease, Octapharma continues to carry out clinical trials to better understand the clinical efficacy and safety of wilate® in different patient populations

Link to the trial on clinicaltrials.gov

VIP-study

Octapharma sponsored clinical studies

Links to the respective trials on clinicaltrials.gov

WIL-33           WIL-31

Investigator-initiated studies

The von Willebrand factor in pregnancy (VIP) study is a prospective, multicentre, investigator-initiated study aiming to increase our understanding of postpartum bleeding in women with von Willebrand disease.

For more details, visit vipstudy.com or clinicaltrials.gov

Principal Investigators
Jill M. Johnsen MD
Bloodworks, Seattle, WA, USA
Barbara A. Konkle MD
Bloodworks, Seattle, WA, USA
Peter A. Kouides MD
Mary M. Gooley Hemophilia Center, Rochester, NY, USA

A multi-cEntre pilot crossover trial of prophylactic wilate® coMpared to PlacebO for heavy menstrual bleeding in patients with low von WillEbrand factoR and von Willebrand disease (EMPOWER)

Principal Investigators
Michelle Sholzberg MDCM
University of Toronto, Canada

References

  1. Srivastava A et al. Haemophilia 2017; 23:264-72.
  2. Windyga J and von Depka-Prondzinski M. Thromb Haemost 2011; 105:1072-79.
  3. Berntorp E and Windyga J. Haemophilia 2009; 15:122-30.
  4. Nowak-Göttl U et al. Haemophilia 2013; 19:887-92.
  5. Batty P et al. Haemophilia 2014; 20: 846-53.
  6. Khair K et al. Haemophilia 2015; 21:e44-50.
  7. Sholzberg M et al. TH Open 2021; 5:e264-72.